Legal Opinion
Brigman v. Wyeth, Inc.
New Jersey Superior Court Appellate Division
Decided April 7, 2005PublishedCited by 1 opinion
1Opinion of the Court
WALSH, J.S.C.
The court has scheduled thirteen cases for trial on May 31, 2005.1 These cases involve two prescription diet drugs approved *528by the United States Food and Drug Administration (FDA) for the treatment of obesity. The drugs, Pondimin® and Redux™, were marketed by Wyeth, which was formerly known as American Home Products Corporation (AHP). In 1973, the FDA approved the New Drug Application (NDA) for Pondimin®, finding it to be safe and effective for the obesity indication.2 In April 1996, the FDA approved Redux™, the other drug in question, which was thereafter marketed by AHP and…
2Cases cited32 opinions
- Jerry W. Canterbury v. William Thornton Spence and the Washington Hospital Center, a Body CorporateCourt of Appeals for the D.C. Circuit · 1972
- Feldman v. Lederle LaboratoriesSupreme Court of New Jersey · 1984
- Wyeth Laboratories v. ReyesSupreme Court of the United States · 1974
- Reyes v. Wyeth LaboratoriesCourt of Appeals for the Fifth Circuit · 1974
- Seley v. G. D. Searle & Co.Ohio Supreme Court · 1981
27 more not listed; retrieve them via the Exa API.
3Cited by1 opinion
- In Re Diet Drug LitigationNew Jersey Superior Court Appellate Division · 2005